Clinical Trials Logo

APL clinical trials

View clinical trials related to APL.

Filter by:
  • None
  • Page 1

NCT ID: NCT05881265 Recruiting - APL Clinical Trials

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

Start date: May 15, 2023
Phase: Phase 2
Study type: Interventional

Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.

NCT ID: NCT02020161 Recruiting - APL Clinical Trials

Clinical Guidelines for APL Treatment

Start date: June 2012
Phase: Phase 4
Study type: Interventional

Therapeutic guidelines for treatment of patients with de novo APL to be used by every institution that wants to follow them. All patients who are reported may be retrospectively analyzed